Drug Pipeline News

>

Latest News

Nirsevimab reduced RSV hospitalizations in infants by 82%, new data shows | Image Credit: © Peter Hansen - © Peter Hansen - stock.adobe.com.
Nirsevimab reduced RSV hospitalizations in infants by 82%, new data show

May 2nd 2024

The new data, published in The Lancet, showed that nirsevimab substantially reduced RSV hospitalizations.

BLA resubmitted for lebrikizumab to treat AD patients 12 years and up | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.
BLA resubmitted for lebrikizumab to treat AD patients 12 years and up

April 30th 2024

FDA approves mavorixafor as first drug for WHIM syndrome | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves mavorixafor as first drug for WHIM syndrome

April 29th 2024

FDA accepts sNDA for tapinarof cream, 1% to treat AD in children 2 years and up | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.
FDA accepts sNDA for tapinarof cream, 1% to treat AD in children 2 years and up

April 29th 2024

FDA approves diazepam for seizure clusters in patients 2 to 5 years | Image Credit: © Calin - © Calin - stock.adobe.com.
FDA approves diazepam for seizure clusters in patients 2 to 5 years

April 29th 2024

Latest CME Events & Activities

18th Annual Controversies in Modern Eye Care

May 4, 2024

Register Now!

Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma

View More

Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer

View More

(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations

View More

Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

View More

Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse

View More

(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis

View More

Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy

View More

(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis

View More

Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference

View More

(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention

View More

(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention

View More

Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis

View More

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis

View More

Understanding RSV: What You Need to Know to Prevent and Treat Respiratory Syncytial Virus in Your Patients

View More

Advances In™ Schizophrenia: Expanding the Therapeutic Landscape

View More

Expert Illustrations & Commentaries™: Visualizing New Therapeutic Targets in Schizophrenia

View More

Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines

View More

Medical Crossfire™: How Do We Implement Personalized Treatment for Colorectal Cancer in the Community?

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Multiple Myeloma from the Summer Meetings

View More

BURST Expert Illustrations & Commentaries™: Tissue Factor Pathway Inhibition—A Visual Journey into the Science Behind Anti-TFPI Therapy for Hemophilia

View More

Oncology Briefings™: Updates in the Care of Patients with ITP – Evaluating the Role of the Nurse

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

View More

© 2024 MJH Life Sciences

All rights reserved.